Despite decades of laboratory, epidemiological and clinical research, breast cancer
incidence continues to rise. Breast cancer remains the leading cancer-related cause of …

High-grade serous ovarian cancer, also known as high-grade serous carcinoma (HGSC), is
the most common and deadliest type of ovarian cancer. HGSC appears to arise from the …

The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and
Pancreatic focus primarily on assessment of pathogenic or likely pathogenic variants …

“The 2022 Hormone Therapy Position Statement of The North American Menopause
Society”(NAMS) updates “The 2017 Hormone Therapy Position Statement of The North …

Importance Potentially harmful mutations of the breast cancer susceptibility 1 and 2 genes
(BRCA1/2) are associated with increased risk for breast, ovarian, fallopian tube, and …

Background Retrospective studies provide conflicting interpretations of the effect of inherited
genetic factors on the prognosis of patients with breast cancer. The primary aim of this study …

PTEN, CDH1, STK11, MLH1, MSH2, MSH6 and PMS2. The cancer risk association with
other genes, such as PALB2, CHEK2, ATM, RAD51C, RAD51D and BRIP1, is still under …

Financial Disclosure Prof. Menon has stock ownership and has received research funding
from Abcodia Ltd, a UCL spinout company with an interest in biomarkers and commercial …

Background In healthy BRCA1/2 mutation carriers, bilateral risk-reducing mastectomy
(BRRM) strongly reduces the risk of developing breast cancer (BC); however, no clear …

The risk of breast and ovarian cancer among women with mutations such as BRCA1 and
BRCA2 mutations can be mitigated by operations to remove the organs at greatest risk. Data …